Product Specifications: Item# 1021: Recombinant HIV-1 MN Envelope Glycoprotein gp120 (Baculovirus). Concentration: See vial Mass/vial: 100ug Diluent: PBS Purity: >95% Stabilizer: None Preservative: None Storage: -75°C Physical State: Frozen Liquid Stability: At least 24 months at -75°C. Applications: Human diagnostics, CD4 binding, Drug screening, Human T-cell CD4 studies. Description: Gene cloned from T-cell-tropic HIV-1 MN strain and the full length recombinant envelope gp120 glycoprotein produced in the Baculovirus Expression System. Purification: This protein is purified by immuno-affinity chromatography to >95% purity as determined by SDS-PAGE, reduced. Specificity: This protein binds to murine monoclonal antibodies of defined epitope specificity and HIV-1 converted human serum polyclonal antibodies in ELISA and Western ELISA. Biological Activity: This protein binds to human T-cell receptor CD4 in ELISA and Western ELISA as determined by CD4/gp120/Anti gp120 mAb-peroxidase capture ELISA. This protein activates human T-Lymphocytes (CD4+, CD4-), in vitro, as measured by RNA synthesis during G0 to G1 transition phase of antigen-binding competent cells. Application and Instructions for use: Recommended concentrations for use are approximate values. A dose dependent response assay should be performed to determine the optimal concentration for use in specific applications. ELISA and Western ELISA require 10-100ng protein depending on the nature and affinity of the detection reagent. Human serum polyclonal antibodies yield titers of 1:1000 or greater at 10-100ng of immobilized protein under standard ELISA conditions. Related Clinical Trials Official Title: A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults Intervention: Biological: MN rgp120/HIV-1 and A244 rgp120/HIV-1, QS-21, rgp120/HIV-1MN Group 1: low-dose MN rsgp120/HIV-1 plus QS-21 (13 volunteers). Group 2: high-dose MN rsgp120/HIV-1 plus QS-21 (13 volunteers). Group 3: AIDSVAX B/E (injection contains each of the two vaccine components, HIV-1 MN rgp120 and A244 rgp120/HIV-1) plus QS-21 plus alum (13 volunteers). Group 4: high-dose MN rgp120/HIV-1 plus QS-21 plus alum (13 volunteers). Group 5: placebo plus QS-21 (8 volunteers). Volunteers will be closely monitored after each immunization and followed for a minimum of 12 months after the initial immunization.
